BIOSPECIMENS AND XENOGRAFT

生物样本和异种移植物

• 批准号: 10220873
• 负责人: JEROME RITZ
• 金额: $ 2.06万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-19 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10220873
• 关键词: Biological Assay; Bone Marrow; Cells; Clinical; Clinical Research Protocols; Collaborations; Collection; Core Facility; Cryopreservation; Cytogenetics; DNA; DNA sequencing; Databases; Development; Diagnosis; Enrollment; Goals; Hematologic Neoplasms; Immunology; Immunophenotyping; Infrastructure; Laboratories; Menin; Mission; Molecular; Mononuclear; Myeloid Leukemia; Myeloproliferative disease; Pathologic; Patients; Plasma; Play; Protocols documentation; Reagent; Reproduction spores; Research; Research Personnel; Research Project Grants; Resources; Role; SYK gene; Sampling; Specimen; Spliceosomes; Testing; Tissue Banks; Transplant Recipients; Transplantation; Work; Xenograft Model; Xenograft procedure; experience; experimental study; falls; improved; in vitro Assay; in vivo Model; leukemia; molecular marker; novel; novel therapeutics; open source; patient derived xenograft model; preclinical trial; preservation; prospective; repository; success; transcriptome sequencing; web site

Abstract The major goals of Core 2 are to provide the SPORE with the infrastructure and professional expertise needed to bank, characterize and distribute primary specimens and patient-derived xenograft (PDX) models. These will be prospectively collected from patients through established protocols developed by the Administrative Core (Core 1), assayed using novel molecular biomarker tests by the Translational Core (Core 3) and serve as essential reagents for each of the Research Projects. Core 2 will be jointly directed by Drs. Jerome Ritz and Dr. David Weinstock. Dr. Jerome Ritz has worked in leukemia and transplant research at DFCI for more than 30 years and has extensive experience in cell collection, processing, cryopreservation, flow cytometric analysis and purification, transplant immunology, and database development. Dr. Ritz is currently the Executive Director of the Connell O'Reilly Cell Manipulation Core Facility (CMCF) at DFCI. The Pasquarello Tissue Bank for Hematologic Malignancies was established as a unit of the CMCF in 2001 and will be responsible for processing, banking and distribution of primary myeloid malignancies for this SPORE. This resource has already acquired over 4,000 bone marrow samples from over 1,500 unique patients with myeloid leukemias that are available for use by SPORE investigators. Dr. Weinstock directs the DFCI Hematologic Malignancy PDX repository, which already contains >300 transplantable PDX models that have been viably cryopreserved and are available for SPORE investigators. These are fully characterized by whole transcriptome sequencing, DNA sequencing, immunophenotyping and other molecular assays. Existing patient samples and PDX lines have already been shared with Project investigators. Moreover, the Core has extensive experience with utilizing primary patient specimens for in vitro assays and PDX models for in vivo pre-clinical trials of novel therapies. Aim 1 of the Core is to acquire primary samples from patients with myeloid malignancies enrolled in clinical research protocols and to isolate and preserve viable mononuclear cells, DNA and plasma. Aim 2 is to establish, characterize, and distribute xenograft models of myeloid malignancies and facilitate pre-clinical trials in collaboration with the Projects. Aim 3 is to maintain annotated databases containing pathologic, cytogenetic and molecular information for clinical samples and xenografts obtained from patients with myeloid malignancies. By successfully pursuing these aims, the Core plays an essential role in the success of the SPORE and its collective efforts to improve the diagnosis and treatment of patients with myeloid neoplasms.

摘要 核心2的主要目标是为孢子提供所需的基础设施和专业知识 保存、鉴定和分发原始标本和患者来源的异种移植(PDX)模型。这些 将通过行政部门制定的既定方案从患者那里前瞻性地收集 核心(核心1)，由翻译核心(核心3)使用新的分子生物标志物测试进行检测，并用作 每个研究项目的基本试剂。核心2将由杰罗姆·里茨博士和 大卫·温斯托克医生。杰罗姆·里茨博士在DFCI从事白血病和移植研究已超过 30年，在细胞采集、加工、冷冻保存、流式细胞仪分析等方面有丰富的经验 以及纯化、移植免疫学和数据库开发。里茨博士目前是执行董事 DFCI康奈尔·奥赖利细胞操纵核心设施(CMCF)主任。帕斯夸雷洛组织银行 恶性血液病中心成立于2001年，是CMCF的一个单位，将负责 该孢子的原发髓系恶性肿瘤的加工、储存和分布。此资源具有 已经从1500多名独特的髓系白血病患者那里获得了4000多份骨髓样本 可供孢子调查人员使用。温斯托克博士指导DFCI血液恶性肿瘤 PDX存储库，其中已包含&gt；300可移植的已以可见方式冷冻保存的PDX模型 并可供孢子调查人员使用。这些都是通过完整的转录组测序来充分表征的， DNA测序、免疫表型和其他分子分析。现有的患者样本和PDX系列 已与项目调查人员分享。此外，Core拥有丰富的经验， 利用原发患者标本进行体外分析和PDX模型进行体内临床前试验 治疗。CORE的目标1是从登记的髓系恶性肿瘤患者中获取原始样本 临床研究方案，并分离和保存可存活的单个核细胞、DNA和血浆。目标2是 建立、鉴定和分发髓系恶性肿瘤的异种移植模型并促进临床前试验 与这些项目合作。目标3是维护包含病理、细胞遗传学的带注释的数据库 和来自髓系患者的临床样本和异种移植物的分子信息 恶性肿瘤。通过成功地实现这些目标，核心在成功实现 孢子及其改善髓系肿瘤患者诊断和治疗的集体努力。